France-based mid-market and growth investor Eurazeo is joining Excelya, a European CRO, as a lead investor alongside its management team to support the group in continuing its development and pursuit of external growth ambitions.
Founded in 2014 by François Moisson and Frédéric Paqueville, Excelya has a comprehensive service platform covering all functions required to position itself as a full-service CRO.
“Together, we will accelerate our growth, strengthen our presence in Europe, and continue to innovate to address the major challenges of clinical research,” said Moisson, CEO of Excelya.
Eurazeo’s investment, led by the Flex Financing team, aims to accelerate Excelya’s European expansion, notably through targeted external growth. The group aspires to become the European leader in clinical research. It also supports a management transition marked by Paqueville’s decision to step back from his operational role in favour of key managers working alongside Moisson.
“This investment in Excelya reflects our commitment to supporting European champions in high-impact sectors,” said Valérie Ducourty, managing director Eurazeo – Flex Financing.
The financing of the transaction is supplemented by bank debt coordinated by Banque Populaire Val de France and Banque Populaire Rives de Paris, with the participation of BNP Paribas, Crédit Lyonnais, and Société Générale.
Press release: EURAZEO supports EXCELYA in a New phase of Development – Excelya